Cell and Gene Therapy Answers: The critical role of flow cytometry in adoptive cell therapies

Adoptive cell therapy (ACT) is a promising type of immunotherapy that involves engineering a patient's immune cells to recognize and attack their cancer. As this field continues to grow, researchers are focused on refining the process to make ACT more effective in supporting the patient immune response. One critical tool for developing better ACT treatments is flow cytometry. To learn more about how flow cytometry enables advances in ACTs, we spoke with Leanne Flye, associate director of scientific operations, general laboratory, at Labcorp.

Labcorp laboratories participate in company’s first-ever honey tasting competition

Beekeeping is the buzz around a number of our sites, and recently Labcorp hosted its first ever honey tasting competition.

Graphical Summary: Cancer-testis antigen burden (CTAB): A novel biomarker of tumor-associated antigens in lung cancer

Renca: A syngeneic renal cancer mouse model for testing immunotherapies

Renal cell carcinoma (RCC) primarily affects individuals aged 60 to 70 years, with men being twice as likely as women to develop the disease. Accounting for 3% of all adult cancers, RCC comprises multiple histological subtypes. Due to the asymptomatic nature of early-stage RCC, misdiagnosis and inadequate screening methods, over 50% of RCC cases are detected incidentally, and approximately 30% of patients are diagnosed with metastatic RCC. Recent advancements in the development of targeted therapies and immunotherapies to treat cancer warrant the need for an effective preclinical model with an intact and functional immune system, enabling the study of therapy-driven immune responses and tumor-induced immunosuppression.1 The Renca cell line, originating from a spontaneous renal adenocarcinoma of Balb/c mice, is a highly aggressive renal cancer cell line particularly valuable for evaluating novel immunotherapies, making it an essential tool in RCC research.2

Nonclinical Solutions - Genetic Toxicology Studies

Learn more about Labcorp's expanded genetic toxicology solutions.

Molecular Tumor Board: 52-year-old male with colon cancer and POLE P286R alteration

Did you know that a subset of patients with microsatellite-stable (MSS) colon cancer have POLE/POLD1 mutations that are associated with high clinical response to immunotherapy?

Join us for this molecular tumor board where we reviewed a case of metastatic MSS-colon cancer with a POLE mutation and high tumor mutational burden, detected on a comprehensive genomic and immune profiling (CGIP) platform. We discuss the incidence and therapeutic significance of POLE/POLD1 proofreading deficiency mutations in patients with colon cancer.